Abstracts

2^nd Annual PEPFAR Uganda Science Summit Reaching and Maintaining Epidemic Control 19 January 2021Kampala Uganda (Virtual)

Once Daily DOLUTEGRAVIR in Young People vs Standard Therapy:
ODYSSEY Study by Cissy Kityo Mutuluuza

CROI 2021 – Conference on Retroviruses and Opportunistic Infections

March 6 – March 10

1. Nucleosides and Darunavir/ Dolutegravir in Africa (NADIA) Trial: 48 wks primary outcome. Nicholas Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe, ApoloBalyegisawa, Arvind Kaimal, Grace Mirembe, PhionahTukamushabe, Gilbert Ategeka, James Hakim, Henry Mugerwa, Abraham Siika, JescaAsienzo, Barbara Castelnuovo, Agnes Kiragga, Andrew Kambugu; for the Nucleosides and Darunavir/Dolutegravir in Africa (NADIA) Trial Team

2. Sex modifies the association between HIV and coronary artery disease in Uganda.SungheeMargevicius, Cissy Kityo, RashidahNazzinda, Marcio S. Bittencourt, Geoffrey Erem, Sophie Nalukwago, Moises A. Huaman, Brian Ghoshhajra, Mark Siedner, Steven M. Juchnowski, David A. Zidar, Grace A. McComsey, Chris T. Longenecker.

3. Abstract for main trial ODYSSEY results titled ‘’Dolutegravir-based ART is superior to NNRTI/PI-based ART in children and adolescents’’– Oralpresention at the virtual CROI, on 10^th March 2021.

4. Interactive Session: Case-Based Discussion on Weight Gain in HIV and Antiretroviral Therapy– Panelists included; Jane O-Halloran, Washington University St Louis, MO, USAGrace McComsey, Case Western Reserve University, Cleveland, OH, USA. Sadaf Farooqi, University of Cambridge, Cambridge, UK. Cissy Kityo, Joint Clinical Research Centre, Kampala, Uganda. Moderator: Peter Hunt, University of California, San Francisco, USA

WHO ECHO Meeting on Pediatric and Adolescent HIV Treatment and Care: Update on DTG: Odyssey Trial Results and DTG Introduction.6 April 2021

1. Dolutegravir-based ART is superior to NNRTI- or PI-based ART in children and adolescents: The ODYSSEY trial. Cissy Kityo, JCRC, Hilda Mujuru, The University of Zimbabwe Clinical Research Centre on behalf of the ODYSSEY Trial Team.

2. PentaTr@ining Uganda 2021: Online Course: 12^th – 15^th April, 2021

3. Impact of COVID-19 on HIV services – Henry Mugerwa

4. Epidemiology of HIV – William Tamale.

5. Case presentation: ART Adherence – Shafic Makumbi

6. HIV Resistance & 2^nd lineART– Francis Ssali

7. CASE Presentation: Drug Toxicity / Hypersensitivity – Diana Rutebarika

8. Impact of paediatric HIV and TB research in Uganda – Victor Musiime

9. CASE Presentation: TB, Cryptococcal Meningitis and Treatment Failure – Rashida Nazzinda.

World Health Summit: GENE THERAPY RESEARCH IN AFRICA, Regional meeting Africa. June 27-30, 2021 Towards Access for All: The Global Gene Therapy Initiative (GGTI) Working Group. presenter:Cissy Kityo

11th IAS Conference on HIV Science18-21 July 2021

1.
Neuropsychiatric manifestations and sleep disturbances in children and
adolescents randomised to dolutegravir-based ART vs standard-of-care in
the ODYSSEY trial”, has been accepted for an on-demand oral abstract
presentation.
Ford D, Gibb D, Shakeshaft Clare, Turkova Anna, SarfatiT, Kityo CM,
MusiimeV, LugemwaA ,Kekitiinwa A, Musoke P, Barlow L,COT M, Ariavae V,
Nigel K, Behuhuma O, Mujuru H, Thanyawee P, Welch S, Ball C, Band S,
Koenigs C, Kobbe R. accepted for an on-demand oral abstract presentation.

2.

Weight gain in children and adolescents on dolutegravir vs standard of
care in the ODYSSEY trial”,
Ford D, Gibb D, Shakeshaft Clare, Turkova Anna, Sarfati T, Kityo CM,
Musiime V, Lugemwa A, Kekitiinwa A, Musoke P, Barlow L, COTM, Ariavae V,
Nigel K, Behuhuma O, Mujuru H, ThanyaweeP,WelchS,BallC,BandS,KoenigsC,Kobbe
R.

3. No age-related difference in dolutegravir metabolic glucuronidation
ratio in children between 3 months and 18 years old in the ODYSSEY trial.
Ford D, Gibb D, Shakeshaft C, Turkova A,
SarfatiT,KityoCM,MusiimeV,LugemwaA,KekitiinwaA,MusokeP,Barlow L,COT
M,AriavaeV,NigelK,BehuhumaO,MujuruH,ThanyaweeP,WelchS,BallC,BandS,KoenigsC,Kobbe
R. Abstract accepted for e-poster

4. Effect of dolutegravir on folate and vitamin B12 status among
HIV-infected children and adolescents in the ODYSSEY trial. Ford D, Gibb D,
Shakeshaft Clare, Turkova Anna, SarfatiT, Kityo CM, Musiime V, Lugemwa A,
Kekitiinwa A, Musoke P, Barlow
L,COTM,AriavaeV,NigelK,BehuhumaO,MujuruH,ThanyaweeP,WelchS,BallC,BandS,Koenigs
C, Kobbe R. accepted for e-poster

5.
IAS 2021 late breaker abstract;

Lower HIV reservoir size in individuals who maintain higher CD4+ T
cells counts prior to antiretroviral therapy initiation: The Strategic
Timing of Antiretroviral Treatment (START) HIV reservoir study.
A Rasmussen, Sunil K Ahuja, Locadiah Kuwanda, Michael J. Vjecha, Fleur
Hudson, Luxshimi Lal, Ajantha Rhodes, Sarah Palmer, Paula Auberson-Munderi,
Henry Mugerwa, Robin Wood, Sharlaa Badal-Faesen, Sandy Pillay, Rosie
Mngqibisa, Alberto LaRosa, Jose Hildago, Kathy Petoumenos, Chris Chiu,
Joseph Lutaakome, Jonathan Kitsona, Esther Kabaswaga, Pietro Pala, Carmela
Ganoza, Katie Fisher, Christina Chang, Jim Neaton, Sharon R Lewin, Edwina J
Wright. Was accepted as a late-breaker E-Poster. Thomas.

6.

Virological failures and genotypic resistance in children and
adolescents randomised to dolutegravir-based ART vs. standard-of-care
in the ODYSSEY trial
Cissy Kityo, Ellen White, Anna Turkova, Hilda A Mujuru,Immaculate
Nankya,Ben Wynne, Shabinah Ali Adeodata Kekitiinwa , Abbas
Lugemwa,Elizabeth Kaudha,Afaaf Liberty, Haseena Cassim,Moherndran Archary,
Mark Cotton,Linda Barlow-Mosha,Tim R Cressey Chaiwat Ngampiyasakul, Ussanee
Srirompotong,Osee Behuhuma ,Yacine Saidi Alasdair Bamford, Robin
Kobbe,Pablo Rojo, Carlo Giaquinto, Diana M Gibb ,Deborah Ford- e- poster. Presenter: Cissy Kityo.

International Workshop on HIV Pediatrics 2021 16-17^th July 2021

The following abstracts were submitted on 23^rd April:

7.
Neuropsychiatric manifestations and sleep disturbances in children and
adolescents randomised to dolutegravir-based ART vs standard-of-care in
the ODYSSEY trial.

: Avy Violari, Adeodata Kekitiinwa, Ellen White, Vivian
Mumbiro, Diana A Rutebarika, Els Dobbels, Hajira Kataike, Tumelo Moloantoa,
Lorna Atwine, Rashidah Nazzinda, Ritah Mbabazi, Suparat Kanjanavanit,
Nozibusiso Rejoice Mosia, Sathaporn Na-Rajsimax, Pornchai Techakunakorn,
Shamim Nakabuye, Thanyawee Puthanakit, Theresa Smit, Robin Kobbe, Clàudia
Fortuny, Ennie Chidziva, Winnie Nansamba, Brenda Kakayi, Dickson Bbuye,
Tatiana Sarfati, Clare Shakeshaft, Alexandra Coelho, Yacine Saïdi, Abbas
Lugemwa, Nigel Klein, Hilda A Mujuru, Mutsa Bwakura- Dangarembizi, Victor
Musiime, Mark Cotton, Carlo Giaquinto, Pablo Rojo, Diana M Gibb, Deborah
Ford, Anna Turkova, the ODYSSEY trial team

8.

Weight gain in children and adolescents on dolutegravir vs standard of
care in the ODYSSEY trial.

Hilda A Mujuru, Abbas Lugemwa, Thanyawee Puthanakit, Pauline Amuge , Cissy
Kityo, Alexandra Compagnucci ,Ebrahim Variava, Adeodata Kekitiinwa, Victor
Musiime, Linda Barlow-Mosha, Chaiwat Ngampiyaskul , Peter Zuidewind, Julius
Tumusiime , Rosie Mngqbisa , Elizabeth Kaudha, Ngundu Osee Behuhuma, Hajira
Kataike, Godfrey Musoro, Annet Nandudu, Mutsa Bwakura, Grace Miriam
Ahimbisibwe, Pradthana Ounchanum, Alice Mulindwa, Rashida Nazzinda, Mark
Ssenyonga, Suparat Kanjanavanit, Kusum Nathoo, Shafic Makumbi, Siva
Danaviah, Shamim Nakabuye, Suwalai Chalermpantmetagul, Diana Antonia
Rutebarika, Stella Nalusiba, Ussanee Srirompotong , Shabinah Ali, Ben
Wynne, Yoann Riault, Steve Welch, Tim R Cressey, Avy Violari, Carlo
Giaquinto, Pablo Rojo, Diana M Gibb, Deborah Ford, Anna Turkova, the
ODYSSEY trial team

9.
Effect of dolutegravir on folate and vitamin B12 status among
HIV-infected children and adolescents in the ODYSSEY trial.

Linda Barlow-Mosha, Grace Miriam Ahimbisibwe, Elizabeth Chappell, Pauline
Mary Amuge, Annet Nanduudu, Elizabeth Kaudha, Timothy Amukele, David
Balamusani, Bosco Kafufu, Audrey Nimwesiga, Cissy Kityo, Adeodata R
Kekitiinwa, Rosemary Namwanje, Gladys Kasangaki, Alice Mulindwa, Gerald
Agaba Muzorah, Dickson Bbuye , Victor Musiime, Emmanuel Mujyambere, Rebecca
Sakwa, Disan Mulima, Sarah Nakabuye, Josephine Namusanje, Richard Isabirye,
Mariam Nabalamba, Barbara Musoke Nakirya, Monica Nolan, Carlo Giaquinto,
Diana M Gibb, Deborah Ford, Philippa Musoke, Anna Turkova, the ODYSSEY
trial team

10.

Virological failures and genotypic resistance in children and
adolescents randomised to dolutegravir-based ART vs. standard-of-care
in the ODYSSEY trial.

Cissy Kityo , Ellen White ,Anna Turkova ,Hilda A Mujuru, Immaculate Nankya,
Ben Wynne, Shabinah Ali, Adeodata Kekitiinwa , Abbas Lugemwa, Elizabeth
Kaudha, Afaaf Liberty, Haseena Cassim, Mohern Archary, Mark Cotton, Linda
Barlow-Mosha, Tim R Cressey, Chaiwat Ngampiyasakul, Ussanee Srirompotong,
Osee Behuhuma, Yacine Saidi, Alasdair Bamford, Robin Kobbe , Pablo Rojo,
Carlo Giaquinto, Diana M Gibb, Deborah Ford

11.

A randomised comparison of DTG-based ART vs Standard of Care in infants
and young children living with HIV weighing 3 to 14kg: results from the
ODYSSEY trial .

Abbas Lugemwa1, Hilda Mujuru2, Ben Wynne3, Avy Violari4, Adeodata R
Kekitiinwa 5, Cissy M Kityo 6, MoherndranArchary 7, Ebrahim Variava 8,
Tatiana Sarfati 3, Clare Shakeshaft 3, Rebecca Turner 3, Kusum Nathoo 2,
EnnieChidziva2, Lorna Atwine1, Nastassja Ramsagar4, AfaafLiberty 4, Pauline
Amuge 5, Elizabeth Kaudha 6, Annet Nanduudu 6, Rosie Mngqibisa7, Rejoice
Mosia7, Mark F Cotton 9, Tim R Cressey 10, Thanyawee Puthanakit 11,
Alexandra Compagnucci 12, Carlo Giaquinto13, Pablo Rojo 14, Deborah Ford 3,
Diana M Gibb3, Anna Turkova3, the ODYSSEY trial team. E—Poster:
A-LB-IAS2021-02539

12.

Long-term Safety & Efficacy of
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir AlafenamideFumarate
(E/C/F/TAF) Single-Tablet Regimen in in Children and Adolescents Living
with HIV.

SuvapornAnugulruengkitt,Aditya H. Gaur,Pope Kosalaraksa,Afaaf
Liberty,Yongwu Shao,Heather Maxwell,Catherine O’Connor,Kathryn Kersey,Jared
Baeten,NatellaRakhmanina,Eva Natukunda. Abstract for presentation to HIV Pediatric workshop.

13.

B/F/TAF IN virologically suppressed adolescents and children: two-year
outcomes in 6 to <18 year olds and six-month outcomes in toddlers

: OralSession Details Abstract Session Pediatric Treatment Friday, Jul 16,
2021.

14.

Towards Access for All: 1st Working Group Report for the Global Gene
Therapy Initiative (GGTI):

Ms Lindsay Androski , Dr Lois Bayigga , Dr Deus Bazira , Dr Eugene Brandon
, Ms Lynda Dee , Dr Steven Deeks , Dr Mohamed Draz , Dr Karine Dubé , Dr
Mark Dybul , Dr Umut Gurkan , Ms Evelyn Harlow , Dr Cissy Kityo , Mr
Michael Louella , Dr Punam Malik , Dr Vikram Mathews , Dr Adrian McKemey ,
Dr Henry Mugerwa , Dr Daniel Muyanja , Ms Olabimpe Olayiwola , Dr Rimas
Orentas , Mr Alex Popovski , Mr Jeff Sheehy , Dr Francis Ssali , Mr Moses
Nsubuga , Dr John Tisdale , Dr Els Verhoeyen , Dr Boro Dropulić submitted
on the 28th May 21

15.

“…So that’s why we hide, we don’t want them to know”—
Challenges to Antiretroviral Therapy Adherence in Kampala, Uganda

Gabrielle Bruser, Isaac Luginaah,Ritah Katasi, Lily Ziyue Zhang, Miriam
Namasinga, Cissy Kityo, Eric Arts Corresponding author: Miss Gabrielle
Bruser. Submitted to Global Health Research and Policy.